When the SPA was signed on 20 November 2020, the respective Heads made the following comments :
Dimitris Moulavasilis, Diaverum CEO, said: “It is a great pleasure to welcome ARCA's founder and CEO C.B. Lim, his partners and clinical teams to our Diaverum family. The teams on both sides have done a fantastic job in finalising this partnership while the global COVID-19 pandemic continues. We look forward to combining ARCA's excellent team and services, and Diaverum's care standards and digital capabilities to provide our high quality, life-enhancing renal care services to more patients in Asia.”
C.B. Lim, ARCA’s founder and CEO, added: “The combination of Diaverum and ARCA makes perfect sense. We have focused on growing ARCA to a strong position in Singapore, with additional clinics in Malaysia. Being part of the Group will enable Diaverum to continue growing in the region for years to come, backed by an even stronger combined team. We also look forward to benefiting from Diaverum’s well established clinical and operational procedures and systems, for the benefit of both patients and staff”.
It’s been 18 months since the deal sale closed, and despite Covid-19 related travel restrictions, intense Integration activities have resulted in both parties getting to know each other well, including the Singapore and Malaysia Healthcare and specifically Dialysis Eco-System. At the same time, with everyone’s commitment and efforts, tangible progress has been made, from iRIMS System going live in 2 of our centres, to a Diaverum-designed facility commencing operations in July 2022.
Meanwhile, the Singapore and Malaysia operations have successfully integrated into the various Corporate reporting requirements and timeline. With the recent lifting of travel restrictions, physical visits by various Diaverum Corporate functions rep. have further enhanced and accelerated understanding and progress.
With these positive developments, ARCA looks forward to its objective of riding on the Diaverum platform and raise its game to the next level, while Diaverum can leverage on this enhanced platform to fulfil its growth plans.